A month before a pharmaceutical class action was set for trial, a Philadelphia judge decertified the class of users of the drug Neurontin who were seeking reimbursement from the drug's maker, Warner-Lambert and merger partner Pfizer, after they were prescribed the drug for uses not approved by federal regulators. The judge wrote in his opinion that he granted Pfizer's decertification motion because there was a question of fact about whether each class member had benefited or been harmed from their off-label prescriptions.
February 11, 2009 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
A month before a pharmaceutical class action was set for trial, a Philadelphia judge decertified the class of users of an epilepsy and neuralgia drug seeking reimbursement from the drug’s maker after being prescribed the drug for uses not approved by federal regulators.
Judge Mark I. Bernstein granted a pharmaceutical company defendant’s motion for class decertification in Clark v. Pfizer Monday. The case was set to go to trial March 9.
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
DEPUTY PORT ATTORNEY III Oakland, CA Salary: $17,294 - $21,419/month, 37.5-hr work week Your Port. Your Community. Your Career. Whe...
Stern, Lavinthal & Frankenberg, LLC, is seeking a foreclosure attorney experienced in the NJ and/or NY foreclosure process and default l...
Mineola defense firm seeks attorneys with 3-5 years of actual insurance defense experience to handle complex general liability matters. Sala...
